AI English summary of an SEC filing — figures as filed
Dexcom DXCMThe company said Jacob S. Leach was promoted to President and Chief Operating Officer effective May 9, 2025. Leach continues to report to Kevin Sayer, the Chief Executive Officer and Chairman of the Board.
Key points
AI summaryThe company said Jacob S. Leach was promoted to President and Chief Operating Officer effective May 9, 2025. Leach continues to report to Kevin Sayer, the Chief Executive Officer and Chairman of the Board.
Dexcom said Leach's annual base salary was raised to $800,000, and his target annual cash performance bonus is 100% of his annual base salary. The actual bonus amount will be determined by the Board's compensation committee.
The company said Leach has served as chief operating officer since 2022, with responsibility for end-to-end product development and oversight of executive functions including global operations, research and development, quality management, regulatory and medical affairs. As president, he will also oversee corporate development and strategy.
The company said in a press release that Leach has more than 21 years of leadership experience at Dexcom and has helped steer its biosensing platforms since the launch of its first commercial system. Sayer, chairman and CEO, said Leach has strengthened the company's ability to innovate.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Jacob S. Leach Promoted to President and Chief Operating Officer
The company said Jacob S. Leach was promoted to President and Chief Operating Officer effective May 9, 2025. Leach continues to report to Kevin Sayer, the Chief Executive Officer and Chairman of the Board.
Source · Based on the filing body and exhibits
Annual Base Salary of $800,000 and Target Performance Bonus of 100%
Dexcom said Leach's annual base salary was raised to $800,000, and his target annual cash performance bonus is 100% of his annual base salary. The actual bonus amount will be determined by the Board's compensation committee.
Source · Based on the filing body and exhibits
COO Role and Added President Responsibilities
The company said Leach has served as chief operating officer since 2022, with responsibility for end-to-end product development and oversight of executive functions including global operations, research and development, quality management, regulatory and medical affairs. As president, he will also oversee corporate development and strategy.
Source · Based on the filing body and exhibits
Leach's Experience and Sayer's Comments in the Press Release
The company said in a press release that Leach has more than 21 years of leadership experience at Dexcom and has helped steer its biosensing platforms since the launch of its first commercial system. Sayer, chairman and CEO, said Leach has strengthened the company's ability to innovate.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…